title: An observational study of Yasmin in the management of women with polycystic ovary syndrome.
abstract: BACKGROUND
  Polycystic ovary syndrome (PCOS) is the commonest endocrine disturbance affecting women in the reproductive age group and encompasses signs of hyperandrogenism, menstrual cycle disturbances and obesity. Some of the symptoms of PCOS may be ameliorated by the combined oral contraceptive pill (COCP).
  
  
  METHODS
  A pilot observational study was carried out in a university teaching hospital setting to determine whether the clinical and biochemical features of PCOS are ameliorated by a new COCP, Yasmin, which contains a new progestogen, drosperinone. Treatment with Yasmin was given for 6 months to 17 patients.
  
  
  RESULTS
  Thirteen patients (76%) completed 6 months of therapy. Good cycle control was achieved in all patients. Percentage body fat increased, with no overall change in body mass index. Fasting insulin and triglyceride concentrations rose significantly. Serum total testosterone concentrations fell with a concomitant rise in sex hormone binding globulin levels. Hirsutism scores did not change significantly in the 12 women who were clinically hirsute. There was, however, a significant improvement in the acne scores. Four of the 17 patients dropped out of the trial between Cycles 3 and 5 due to side effects.
  
  
  CONCLUSIONS
  Yasmin provides good cycle control for women with PCOS, with an improvement in acne over 6 months but not in other symptoms of the syndrome.
authors.affiliation: Department of Reproductive Medicine, Leeds General Infirmary, Leeds, UK.
authors.forename: Manisha
authors.initials: M
authors.lastname: Palep-Singh
authors.forename: Karen
authors.initials: K
authors.lastname: Mook
authors.forename: Julian
authors.initials: J
authors.lastname: Barth
authors.forename: Adam
authors.initials: A
authors.lastname: Balen
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000736:Androstenes / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003270:Contraceptive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006784:Hospitals, Teaching; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D019370:Observation; D010865:Pilot Projects; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000736:Androstenes; D003270:Contraceptive Agents; D004338:Drug Combinations; D000451:Mineralocorticoid Receptor Antagonists; C035144:drospirenone